Announcements for the test results in antibody cocktail made today, Monday (11/10) the AstraZeneca.
In particular, as announced by the company, the first injectable protection device against coronavirus, in addition to vaccines, met its main objectives in an advanced phase test, as it helped to reduce the chances of developing severe Covid-19 or death in non-hospitalized patients, as transmitted by APE-MPE.
Coronavirus – AstraZeneca: What it recently announced about a new treatment
It is recalled that in addition to vaccines and antibody cocktails, AstraZeneca performed trials for a new treatment for COVID-19 for people who do not respond well to vaccines because of a weakened immune system.
In particular, as the Anglo-Swedish company announced in early October, a test showed that this drug reduced the risk of COVID-19 symptoms in people by 77%.
Antibody therapy, called AZD7442, could protect people who do not have a strong immune response to COVID-19 vaccines, according to AstraZeneca.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.